|
1.
|
Paoletti X, Burzykowski T, Michiels S,
Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M,
Van Cutsem E and Buyse M: Benefit of adjuvant chemotherapy for
resectable gastric cancer: a meta-analysis. JAMA. 303:1729–1737.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Ochsenbein AF: Principles of tumor
immunosurveillance and implications for immunotherapy. Cancer Gene
Ther. 9:1043–1055. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Kirkwood JM, Butterfield LH, Tarhini AA,
Zarour H, Kalinski P and Ferrone S: Immunotherapy of cancer in
2012. CA Cancer J Clin. 62:309–335. 2012. View Article : Google Scholar
|
|
4.
|
Rosenberg SA, Yang JC and Restifo NP:
Cancer immunotherapy: moving beyond current vaccines. Nat Med.
10:909–915. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Toes RE, Blom RJ, Offringa R, Kast WM and
Melief CJ: Enhanced tumor outgrowth after peptide vaccination.
Functional deletion of tumor-specific CTL induced by peptide
vaccination can lead to the inability to reject tumors. J Immunol.
156:3911–3918. 1996.PubMed/NCBI
|
|
6.
|
Toes RE, Offringa R, Blom RJ, Melief CJ
and Kast WM: Peptide vaccination can lead to enhanced tumor growth
through specific T-cell tolerance induction. Proc Natl Acad Sci
USA. 93:7855–7860. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Muraoka D, Kato T, Wang L, Maeda Y,
Noguchi T, Harada N, Takeda K, Yagita H, Guillaume P, Luescher I,
Old LJ, Shiku H and Nishikawa H: Peptide vaccine induces enhanced
tumor growth associated with apoptosis induction in CD8+
T cells. J Immunol. 185:3768–3776. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Bour H, Horvath C, Lurquin C, Cerottini JC
and MacDonald HR: Differential requirement for CD4 help in the
development of an antigen-specific CD8+ T cell response
depending on the route of immunization. J Immunol. 160:5522–5529.
1998.PubMed/NCBI
|
|
9.
|
Pardoll DM and Topalian SL: The role of
CD4+ T cell responses in antitumor immunity. Curr Opin
Immunol. 10:588–594. 1998.
|
|
10.
|
Toes RE, Ossendorp F, Offringa R and
Melief CJ: CD4 T cells and their role in antitumor immune
responses. J Exp Med. 189:753–756. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Janssen EM, Lemmens EE, Wolfe T, Christen
U, von Herrath MG and Schoenberger SP: CD4+ T cells are
required for secondary expansion and memory in CD8+ T
lymphocytes. Nature. 421:852–856. 2003.PubMed/NCBI
|
|
12.
|
Shedlock DJ and Shen H: Requirement for
CD4 T cell help in generating functional CD8 T cell memory.
Science. 300:337–339. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Lizée G, Rasvanyi LG, Overwijik WW and Hwu
P: Immunosuppression in melanoma immunotherapy: potential
opportunities for intervention. Clin Cancer Res. 12:S2359–S2365.
2006.PubMed/NCBI
|
|
14.
|
Jackson AM, Mulcathy LA, Zhu XW, O’Donnell
D and Patel PM: Tumor-mediated disruption of dendritic cell
function: inhibiting the MEK1/2-p44/42 axis restores IL-12
production and Th1-generation. Int J Cancer. 123:623–632. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Yang DH, Park JS, Jin CJ, Kang HK, Nam JH,
Rhee JH, Kim YK, Chung SY, Choi SJN, Kim HJ, Chung IJ and Lee JJ:
The dysfunction and abnormal signaling pathway of dendritic cells
loaded by tumor antigen can be overcome by neutralizing VEGF in
multiple myeloma. Leuk Res. 33:665–670. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Schnurr M, Toy T, Stoitzner P, Cameron P,
Shin A, Beecroft T, Davis ID, Cebon J and Maraskovsky E: ATP
gradients inhibit the migratory capacity of specific human
dendritic cell types: implications for P2Y11 receptor signaling.
Blood. 102:613–620. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Pinzon-Charry A, Maxwell T and Lopez JA:
Dendritic cell dysfunction in cancer: a mechanism for
immunosuppression. Immunol Cell Biol. 83:451–461. 2005. View Article : Google Scholar
|
|
18.
|
Bennaceur K, Popa I, Portoukalian J,
Bethier-Vergnes O and Peguet-Navarro J: Melanoma-derived
gangliosides impair migratory and antigen-presenting function of
human epidermal Langerhans cells and induce their apoptosis. Int
Immunol. 18:879–886. 2006. View Article : Google Scholar
|
|
19.
|
Stewart LM, Hirst M, López-Ferber M,
Merryweather AT, Cayley PJ and Possee RD: Construction of an
improved baculovirus insecticide containing an insect-specific
toxin gene. Nature. 352:85–88. 1991. View
Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Jennifer SC, Mark LH, Trevor W, Rosemary
SH, David G, Bernadette MG, Timothy MC, Robert DP, Cayley PJ and
Bishop DHL: Field trial of a genetically improved baculovirus
insecticide. Nature. 370:138–140. 1994. View Article : Google Scholar
|
|
21.
|
Matsuura Y, Possee RD, Overton HA and
Bishop DHL: Baculovirus expression vectors: the requirements for
high level expression of proteins, including glycoproteins. J Gen
Virol. 68:1233–1250. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Luckow VA and Summers MD: Trends in the
development of baculovirus expression vectors. Biotechnology.
6:47–55. 1988. View Article : Google Scholar
|
|
23.
|
Hofmann C, Sandig V, Gennings G, Rudolph
M, Schlag P and Strauss M: Efficient gene transfer into human
hepatocytes by baculovirus vectors. Proc Natl Acad Sci USA.
92:10099–10103. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Boyce FM and Bucher NLR:
Baculovirus-mediated gene transfer into mammalian cells. Proc Natl
Acad Sci USA. 93:2348–2352. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Sandig V and Strauss M: Liver-directed
gene transfer and application to therapy. J Mol Med. 74:205–212.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Pieroni L and La Monica N: Towards the use
of baculovirus as a gene therapy vector. Curr Opin Mol Ther.
3:464–467. 2001.PubMed/NCBI
|
|
27.
|
Kost TA and Condreay JP: Recombinant
baculoviruses as mammalian gene-delivery vectors. Trends
Biotechnol. 20:173–180. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Gronowski AM, Hilbert DM, Sheehan KCF,
Garotta G and Schreiber RD: Baculovirus stimulates antiviral
effects in mammalian cells. J Virol. 73:9944–9951. 1999.PubMed/NCBI
|
|
29.
|
Beck NB, Sidhu JS and Omiecinski CJ:
Baculovirus vectors repress phenobarbital-mediated gene induction
and stimulate cytokine expression in primary cultures of rat
hepatocytes. Gene Ther. 7:1274–1283. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Kitajima M, Abe T, Miyano-Kurosaki N,
Taniguchi M, Nakayama T and Takaku H: Induction of natural killer
cell-dependent antitumor immunity by the Autographa
californica multiple nuclear polyhedrosis virus. Mol Ther.
16:261–268. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Suzuki T, Chang MO, Kitajima M and Takaku
H: Baculovirus activates murine dendritic cells and induces
non-specific NK cell and T cell immune responses. Cell Immunol.
262:35–43. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Suzuki T, Chang MO, Kitajima M and Takaku
H: Induction of antitumor immunity against mouse carcinoma by
baculovirus-infected dendritic cells. Cell Mol Immunol. 7:440–446.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Schöttker B and Schmidt-Wolf IGH: Pulsing
with blast cell lysate or blast-derived total RNA reverses the
dendritic cell-mediated cytotoxic activity of cytokine-induced
killer cells against allogeneic acute myelogenous leukemia cells.
Ger Med Sci. doi: 10.3205/000141. URN: urn:nbn:de:0183-0001410.
2011.
|
|
34.
|
Reis e Sousa C: Dendritic cells in a
mature age. Nat Rev Immunol. 6:476–483. 2006.PubMed/NCBI
|
|
35.
|
Pasare C and Medzhitov R: Toll
pathway-dependent blockade of CD4+CD25+ T
cell-mediated suppression by dendritic cells. Science.
299:1033–1036. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Shevach EM: Regulatory T cells in
autoimmmunity*. Annu Rev Immunol. 18:423–449. 2000.
View Article : Google Scholar
|
|
37.
|
Maloy KJ and Powrie F: Regulatory T cells
in the control of immune pathology. Nat Immunol. 2:816–822. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Piccirillo CA and Shevach EM: Cutting
edge: control of CD8+ T cell activation by
CD4+CD25+ immunoregulatory cells. J Immunol.
167:1137–1140. 2001.PubMed/NCBI
|
|
39.
|
Sakaguchi S: Naturally arising
Foxp3-expressing CD25+CD4+ regulatory T cells
in immunological tolerance to self and non-self. Nat Immunol.
6:345–352. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Turk MJ, Guevara-Patiño JA, Rizzuto GA,
Engelhorn ME, Sakaguchi S and Houghton AN: Concomitant tumor
immunity to a poorly immunogenic melanoma is prevented by
regulatory T cells. J Exp Med. 200:771–782. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Yu P, Lee Y, Liu W, Krausz T, Chong A,
Schreiber H and Fu YX: Intratumor depletion of CD4+
cells unmasks tumor immunogenicity leading to the rejection of
late-stage tumors. J Exp Med. 201:779–791. 2005.PubMed/NCBI
|
|
42.
|
Tani H, Nishijima M, Ushijima H, Miyamura
T and Matsuura Y: Characterization of cell-surface determinants
important for baculovirus infection. Virology. 279:343–353. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Akira S, Takeda K and Kaisho T: Toll-like
receptors: critical proteins linking innate and acquired immunity.
Nat Immunol. 2:675–680. 2001. View
Article : Google Scholar : PubMed/NCBI
|
